Biotest AG - ESG Rating & Company Profile powered by AI
Jump to the bottom of the webpage for potential risks for Biotest AG based on industry, geography and size. This assessment of Biotest AG was prepared by All Street Sevva using cutting edge NLP. If you are employed by Biotest AG and you would like to licence your ESG aseessment, please contact us.
Biotest AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 6.0, social score of 6.4 and governance score of 4.8.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 541 | Wntresearch AB | 5.8 | High |
| 541 | Zenotech Laboratories Ltd | 5.8 | High |
| 579 | Biotest AG | 5.7 | High |
| 579 | Caplin Point Laboratories Ltd | 5.7 | High |
| 579 | Acasti Pharma Inc | 5.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Biotest AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Biotest AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Biotest AG report the average age of the workforce?
Sign up for free to unlockDoes Biotest AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Biotest AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Biotest AG disclose cybersecurity risks?
Sign up for free to unlockDoes Biotest AG offer flexible work?
Sign up for free to unlockDoes Biotest AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Biotest AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Biotest AG conduct supply chain audits?
Sign up for free to unlockDoes Biotest AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Biotest AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Biotest AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Biotest AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Biotest AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Biotest AG disclose water use targets?
Sign up for free to unlockDoes Biotest AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Biotest AG have a product recall in the last two years?
Sign up for free to unlockDoes Biotest AG disclose incidents of discrimination?
Sign up for free to unlockDoes Biotest AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Biotest AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Biotest AG disclose parental leave metrics?
Sign up for free to unlockDoes Biotest AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Biotest AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Biotest AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Biotest AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Biotest AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Biotest AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Biotest AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Biotest AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Biotest AG disclose its waste policy?
Sign up for free to unlockDoes Biotest AG report according to TCFD requirements?
Sign up for free to unlockDoes Biotest AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Biotest AG disclose energy use targets?
Sign up for free to unlockDoes Biotest AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Biotest AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Biotest AG
These potential risks are based on the size, segment and geographies of the company.
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. As of January 4, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.